Want to see NEO full AI Analyst Report?
NEO Stock Chart & Stats
$13.89
-$0.75(-5.40%)
At close: 4:00 PM EDT
$13.89
-$0.75(-5.40%)
Day’s Range― - ―
52-Week Range$6.24 - $17.08
Previous Close$13.14
Volume1.80M
Average Volume (3M)3.52M
Market Cap
$2.12B
Enterprise Value$2.21K
Total Cash (Recent Filing)$145.54M
Total Debt (Recent Filing)$448.37M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 10, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding128,475,430
10 Day Avg. Volume3,042,403
30 Day Avg. Volume3,521,996
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.80Price Target Upside28.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.18
Revenue Forecast (FY)$800.44M
Bulls Say, Bears Say
Bulls Say
Clinical Testing GrowthClinical testing is the core revenue engine, and 14% growth with higher AUP indicates sustained demand and improved test mix. This supports scale in oncology pathways and provides a durable base for expanding precision diagnostics.
NGS ExpansionRapid NGS growth strengthens NeoGenomics’ position in precision oncology and shifts its mix toward higher-complexity testing. Increasing NGS adoption can support durable revenue expansion as molecular diagnostics become more embedded in cancer care.
Margin And Operational ImprovementMargin expansion alongside automation, digital pathology and laboratory upgrades indicates improving operating leverage. These initiatives can lower unit costs, increase capacity and support more sustainable EBITDA growth as testing volumes scale.
Bears Say
Persistent Net Losses And Negative Free Cash FlowNeoGenomics is growing, but it has not yet converted that growth into consistent GAAP profitability or positive free cash flow. Continued losses constrain internally funded investment and make execution on margin improvement important to long-term flexibility.
Pharma Segment WeaknessWeak biopharma revenue reduces diversification beyond clinical testing and shows that bookings are not yet translating into service revenue. A prolonged slowdown in trial activity or delayed pull-through could temper consolidated growth and resource utilization.
Reimbursement-Dependent Product ScalingRaDaR ST and other advanced assays may offer growth, but reimbursement approval remains a critical gate to adoption and revenue. Pending payer decisions create uncertainty around the timing and magnitude of commercialization for newer diagnostics.
NeoGenomics News
NEO FAQ
What was NeoGenomics Inc.’s price range in the past 12 months?
NeoGenomics Inc. lowest stock price was $6.24 and its highest was $17.07 in the past 12 months.
What is NeoGenomics Inc.’s market cap?
NeoGenomics Inc.’s market cap is $2.12B.
When is NeoGenomics Inc.’s upcoming earnings report date?
NeoGenomics Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 80 days.
How were NeoGenomics Inc.’s earnings last quarter?
NeoGenomics Inc. released its earnings results on Jul 28, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.034 by $0.016.
Is NeoGenomics Inc. overvalued?
According to Wall Street analysts NeoGenomics Inc.’s price is currently Undervalued.
Does NeoGenomics Inc. pay dividends?
NeoGenomics Inc. pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics Inc. dividends here
What is NeoGenomics Inc.’s EPS estimate?
NeoGenomics Inc.’s EPS estimate is 0.05.
How many shares outstanding does NeoGenomics Inc. have?
NeoGenomics Inc. has 128,475,430 shares outstanding.
What happened to NeoGenomics Inc.’s price movement after its last earnings report?
NeoGenomics Inc. reported an EPS of $0.05 in its last earnings report, beating expectations of $0.034. Following the earnings report the stock price went up 13.955%.
Which hedge fund is a major shareholder of NeoGenomics Inc.?
Currently, no hedge funds are holding shares in NEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.80 (28.15% Upside)
$17.80 (28.15% Upside)
Blogger Sentiment
Bullish
NEO Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 885.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $440.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.6%
Last 30 Days ▲ 76.2%
Last 30 Days ▲ 76.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.99%
Trailing 12-Months
Company Description
NeoGenomics Inc.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NEO Company Deck
NEO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial and margin momentum driven by strong NGS and clinical performance, operational efficiencies from the Lab of the Future program, and constructive guidance and capital structure actions. Headwinds were concentrated in the smaller nonclinical/pharma segment (notably a 26% decline in Pharma revenue) and timing-sensitive items (reimbursement for RaDaR ST, a DOJ settlement impact, and a tougher Q3 comp from exiting a high-volume low-value contract). Overall, the company demonstrated durable clinical growth, margin expansion and strengthened liquidity while acknowledging discrete near-term challenges that management plans to address.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$17.80
▲(28.15% Upside)
Technical Analysis
Ownership Overview
0.82% Insiders
26.87% Mutual Funds
38.48% Other Institutional Investors
1.33% Public Companies and
Individual Investors